Monday, May 08, 2017 3:27:43 PM
Elite's Multi-Billion Dollar Platform:
Elite's Current Marketed Products and Pipeline is growing rapidly ! Fully developed its worth Billion$
Start watching for the undisclosed drug filings.
$$$$$$$$$$$$
Elite working on 7 AD opiods concurrently
Elite just one launch from being Cash Low Positive
$Generic Products$$
Commercial Product
Branded Product Equivalent
Therapeutic Category u
1. Hydromorphone Hydrochloride
8 mg Tablets
Dilaudid®
Pain
2. Naltrexone Hydrochloride
50 mg Tablets
Revia®
Opioid Antagonist
3. Phentermine HCl
37.5 mg Tablets
Adipex-P®
Bariatric
4. Phentermine HCI
15 mg and 30 mg Capsules
Adipex-P®
Bariatric
5. Phendimetrazine Tartrate
35 mg Tablets, USP
Bontril®
Bariatric
6. Isradipine
2.5 mg and 5 mg Capsules
N/A
Cardiovascular
7. Hydroxyzine HCI
10 mg, 25 mg, 50 mg Tablets
Atarax®, Vistaril®
Antihistamine
8. Dantrolene Sodium
25 mg, 50 mg and 100 mg Capsules *
Dantrium®
Skeletal Muscle Relaxant
9. Loxapine
5 mg, 10 mg, 25 mg, 50 mg Capsules *
N/A
Antipsychotic
10. Additional Approved ANDA's *
Undisclosed
Undisclosed
* pending manufacturing site transfer
$BRANDED PRODUCTS$$
Commercial Product
Therapeutic Category
Partner
11. Lodrane D®
OTC Allergy
Valeant Pharmaceuticals International, Inc.
$CONTRACT MANUFACTURING$$
Commercial Product
Branded Product Equivalent
Therapeutic Category
Partner
12. Methadone Hydrochloride
10 mg Tablets
Dolophine®
Pain
Ascend Laboratories, LLC
$GENERIC PIPELINE$$
Programs Under Development
Branded Product Equivalent
Therapeutic Category
Development Stage
13. ELI-300 Opioid
Undisclosed
Pain
Early Development
14. ELI-301 Opioid
Undisclosed
Pain
Early Development
15. Oxycodone HCl and Acetaminophen, USP 325 mg
5 mg, 7.5 mg, 10 mg Tablets
Percocet
Pain
Pending FDA Approval
16. Hydrocodone bitartrate and Acetaminophine tablets, 2.5mg/325mg, 5mg/325mg, 7.5mg/325mg and 10mg/325mg tablets
Norco
Pain
Pending FDA Approval
17. Undisclosed Generic
Undisclosed
Undisclosed
Pending FDA Approval
18. Elite/SunGen Generic #1
Undisclosed
CNS Stimulant
In Development
19. Elite/SunGen Generic #2
Undisclosed
CNS Stimulant
In Development
20. Elite/SunGen Generic #3
Undisclosed
Beta-Blocker
In Development
21. Elite/SunGen Generic #4
Undisclosed
Beta-Blocker
In Development
22. Generic Troxyca
Pain
23. Generic Embeda
Pain
24. Generic OxyContin
25. Generic Opana Oxymorphone
Pain
$BRANDED PIPELINE$$
Development Stage
Partner
26. SequestOx™ (ELI-200) Opioid
Pain
NDA Submitted
PDUFA date: July 14, 2016
Epic Pharma LLC
27. ELI-201 ER Opioid
Troxyca equivalent
Pain
Pivotal Bio-equivalence
28. ELI-202 Opioid
Pain
Pivotal Bio-equivalence
29. ELI-216 Opioid ER 24hr (once/day)
Pain
Process Development
30. ELI-400 Opioid
Pain
Process Development
31., ELI-500 Opioid
Pain
Process Development
32. ELI-501 Opioid
Pain
Early Development
33. ELI-600 Opioid
Pain
Process development ELTP
ELTP
Elite's Current Marketed Products and Pipeline is growing rapidly ! Fully developed its worth Billion$
Start watching for the undisclosed drug filings.
$$$$$$$$$$$$
Elite working on 7 AD opiods concurrently
Elite just one launch from being Cash Low Positive
$Generic Products$$
Commercial Product
Branded Product Equivalent
Therapeutic Category u
1. Hydromorphone Hydrochloride
8 mg Tablets
Dilaudid®
Pain
2. Naltrexone Hydrochloride
50 mg Tablets
Revia®
Opioid Antagonist
3. Phentermine HCl
37.5 mg Tablets
Adipex-P®
Bariatric
4. Phentermine HCI
15 mg and 30 mg Capsules
Adipex-P®
Bariatric
5. Phendimetrazine Tartrate
35 mg Tablets, USP
Bontril®
Bariatric
6. Isradipine
2.5 mg and 5 mg Capsules
N/A
Cardiovascular
7. Hydroxyzine HCI
10 mg, 25 mg, 50 mg Tablets
Atarax®, Vistaril®
Antihistamine
8. Dantrolene Sodium
25 mg, 50 mg and 100 mg Capsules *
Dantrium®
Skeletal Muscle Relaxant
9. Loxapine
5 mg, 10 mg, 25 mg, 50 mg Capsules *
N/A
Antipsychotic
10. Additional Approved ANDA's *
Undisclosed
Undisclosed
* pending manufacturing site transfer
$BRANDED PRODUCTS$$
Commercial Product
Therapeutic Category
Partner
11. Lodrane D®
OTC Allergy
Valeant Pharmaceuticals International, Inc.
$CONTRACT MANUFACTURING$$
Commercial Product
Branded Product Equivalent
Therapeutic Category
Partner
12. Methadone Hydrochloride
10 mg Tablets
Dolophine®
Pain
Ascend Laboratories, LLC
$GENERIC PIPELINE$$
Programs Under Development
Branded Product Equivalent
Therapeutic Category
Development Stage
13. ELI-300 Opioid
Undisclosed
Pain
Early Development
14. ELI-301 Opioid
Undisclosed
Pain
Early Development
15. Oxycodone HCl and Acetaminophen, USP 325 mg
5 mg, 7.5 mg, 10 mg Tablets
Percocet
Pain
Pending FDA Approval
16. Hydrocodone bitartrate and Acetaminophine tablets, 2.5mg/325mg, 5mg/325mg, 7.5mg/325mg and 10mg/325mg tablets
Norco
Pain
Pending FDA Approval
17. Undisclosed Generic
Undisclosed
Undisclosed
Pending FDA Approval
18. Elite/SunGen Generic #1
Undisclosed
CNS Stimulant
In Development
19. Elite/SunGen Generic #2
Undisclosed
CNS Stimulant
In Development
20. Elite/SunGen Generic #3
Undisclosed
Beta-Blocker
In Development
21. Elite/SunGen Generic #4
Undisclosed
Beta-Blocker
In Development
22. Generic Troxyca
Pain
23. Generic Embeda
Pain
24. Generic OxyContin
25. Generic Opana Oxymorphone
Pain
$BRANDED PIPELINE$$
Development Stage
Partner
26. SequestOx™ (ELI-200) Opioid
Pain
NDA Submitted
PDUFA date: July 14, 2016
Epic Pharma LLC
27. ELI-201 ER Opioid
Troxyca equivalent
Pain
Pivotal Bio-equivalence
28. ELI-202 Opioid
Pain
Pivotal Bio-equivalence
29. ELI-216 Opioid ER 24hr (once/day)
Pain
Process Development
30. ELI-400 Opioid
Pain
Process Development
31., ELI-500 Opioid
Pain
Process Development
32. ELI-501 Opioid
Pain
Early Development
33. ELI-600 Opioid
Pain
Process development ELTP
ELTP
You Can Tell A Man's Character By The Way He Treats Those Who Can Do Nothing For Him
Recent ELTP News
- Form 8-K - Current report • Edgar (US Regulatory) • 04/02/2026 12:05:23 PM
- Elite Pharmaceuticals Announces Commercial Launch of Methadone Hydrochloride Tablets • Newsfile • 04/02/2026 12:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/17/2026 10:10:32 PM
- Elite Pharmaceuticals, Inc. Reports Financial Results for the Third Quarter of Fiscal Year 2026 (three months ended December 31, 2025) and Provides Conference Call Information • Newsfile • 02/17/2026 09:19:00 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 02/17/2026 09:06:15 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/11/2026 09:35:26 PM
- Elite Pharmaceuticals, Inc. to Host Conference Call to Provide Corporate Update and Discuss Third Quarter 2026 Financial Results on February 18, 2026 • Newsfile • 02/11/2026 09:30:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/13/2026 09:35:20 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/14/2025 10:10:23 PM
- Elite Pharmaceuticals, Inc. Reports Financial Results for the Second Quarter of Fiscal Year 2026 Ended September 30, 2025 and Provides Conference Call Information • Newsfile • 11/14/2025 09:19:00 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/14/2025 09:11:38 PM
- Form 8-K/A - Current report: [Amend] • Edgar (US Regulatory) • 11/12/2025 10:19:32 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/12/2025 12:15:37 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/10/2025 12:15:46 PM
- Elite Pharmaceuticals, Inc. to Host Conference Call to Provide Corporate Update and Discuss Second Quarter 2026 Financial Results on November 17, 2025 • Newsfile • 11/10/2025 12:00:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 08/26/2025 09:17:39 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 08/22/2025 01:39:01 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/14/2025 08:37:09 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/08/2025 08:35:45 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 07/25/2025 10:05:07 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 07/10/2025 08:17:22 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 07/08/2025 08:15:11 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 07/08/2025 02:58:10 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 06/30/2025 08:27:51 PM
- Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] • Edgar (US Regulatory) • 06/30/2025 08:05:59 PM
